康哲药业(00867)：创新药口服小分子JAK1抑制剂Povorcitinib 纳入突破性治疗品种名单

智通财经2025-12-15

智通财经APP讯，康哲药业(00867)发布公告，集团旗下德镁医药有限公司(德镁医药，专业聚焦皮肤健康的创新型医药企业，正申请于香港联合交易所有限公司主板独立上市)拥有相关许可权利的创新口服JAK1抑制剂povorcitinib(拟定中文通用名：磷酸泊沃昔替尼片)(povorcitinib或产品)已获中国国家药品监督管理局(NMPA)药品评审中心批准纳入突破性治疗品种名单，拟定适应症为成人患者非节...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2591264308?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-15 19:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591264308","market":"hk","top_or_hot":-1,"title":"康哲药业(00867)：创新药口服小分子JAK1抑制剂Povorcitinib 纳入突破性治疗品种名单","media":"智通财经","content":"<div>\n<p>智通财经APP讯，康哲药业(00867)发布公告，集团旗下德镁医药有限公司(德镁医药，专业聚焦皮肤健康的创新型医药企业，正申请于香港联合交易所有限公司主板独立上市)拥有相关许可权利的创新口服JAK1抑制剂povorcitinib(拟定中文通用名：磷酸泊沃昔替尼片)(povorcitinib或产品)已获中国国家药品监督管理局(NMPA)药品评审中心批准纳入突破性治疗品种名单，拟定适应症为成人患者非节...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1381734.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康哲药业(00867)：创新药口服小分子JAK1抑制剂Povorcitinib 纳入突破性治疗品种名单</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康哲药业(00867)：创新药口服小分子JAK1抑制剂Povorcitinib 纳入突破性治疗品种名单\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-15 19:49 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1381734.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，康哲药业(00867)发布公告，集团旗下德镁医药有限公司(德镁医药，专业聚焦皮肤健康的创新型医药企业，正申请于香港联合交易所有限公司主板独立上市)拥有相关许可权利的创新口服JAK1抑制剂povorcitinib(拟定中文通用名：磷酸泊沃昔替尼片)(povorcitinib或产品)已获中国国家药品监督管理局(NMPA)药品评审中心批准纳入突破性治疗品种名单，拟定适应症为成人患者非节...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1381734.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999004220.SGD","symbol_name":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1381734.html","article_id":"2591264308","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591264308","pubTimestamp":1765799362,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，康哲药业 发布公告，集团旗下德镁医药有限公司拥有相关许可权利的创新口服JAK1抑制剂povorcitinib已获中国国家药品监督管理局药品评审中心批准纳入突破性治疗品种名单，拟定适应症为成人患者非节段型白癜风。Povorcitinib目前正在海外若干国家进行非节段型白癜风、中重度化脓性汗腺炎和结节性痒疹的3期临床试验。本次该产品获纳入突破性治疗药物品种名单，有望加速其在中国大陆的研发与审评进程。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","IE00BVYPNQ40.USD":"GUINNESS ASIAN EQUITY INCOME \"C\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","06978":"永泰生物-B","IE00BYV24P56.USD":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (USD) ACC","SG9999015978.USD":"利安颠覆性创新基金A","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","00867":"康哲药业","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","BK1161":"生物科技","BK1191":"制药","BK1593":"医美概念股","IE00BVYPNP33.GBP":"GUINNESS ASIAN EQUITY INCOME \"C\" (GBP) ACC","IE00BMCWC346.EUR":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (EUR) ACC","IE00BGHQDM52.EUR":"GUINNESS ASIAN EQUITY INCOME \"C\" (EUR) ACC","BK1574":"生物医药B类股"},"translate_title":"CMS (00867): Innovative drug oral small molecule JAK1 inhibitor Povorcitinib is included in the list of breakthrough therapy varieties","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1.5,"00867":1.5,"06978":1.5},"content_text":"智通财经APP讯，康哲药业(00867)发布公告，集团旗下德镁医药有限公司(德镁医药，专业聚焦皮肤健康的创新型医药企业，正申请于香港联合交易所有限公司主板独立上市)拥有相关许可权利的创新口服JAK1抑制剂povorcitinib(拟定中文通用名：磷酸泊沃昔替尼片)(povorcitinib或产品)已获中国国家药品监督管理局(NMPA)药品评审中心批准纳入突破性治疗品种名单，拟定适应症为成人患者非节段型白癜风。此次认定有望加快该产品的研发与审评进程。Povorcitinib是一种选择性口服小分子JAK1抑制剂，在区域内特定国家/地区拥有物质和用途专利。Povorcitinib目前正在海外若干国家进行非节段型白癜风、中重度化脓性汗腺炎(HS)和结节性痒疹的3期临床试验。另外，治疗哮喘的2期临床试验也在进行中。本次该产品获纳入突破性治疗药物品种名单，有望加速其在中国大陆的研发与审评进程。若于中国获批上市，该产品将有望与德镁医药在售创新药益路取(替瑞奇珠单抗注射液)、在售独家药喜辽妥(多磺酸粘多糖乳膏)及正处于新药上市申请(NDA)阶段的创新药磷酸芦可替尼乳膏形成协同，推动产品快速实现临床和商业价值，惠及更多皮肤疾病患者。此外，该产品还将与外用磷酸芦可替尼乳膏共同为白癜风患者提供差异化、全面的治疗选择。本集团于2024年3月31日，通过德镁医药的附属公司与Incyte就povorcitinib订立合作和许可协议，获得在中国大陆、香港特别行政区、澳门特别行政区、台湾地区及东南亚十一国(区域)研究、开发、注册及商业化产品的独家许可权利，以及在区域内生产产品的非独家许可权利。德镁医药的附属公司已将povorcitinib除中国大陆外的其他区域的相关权利再许可予本集团(不包括德镁医药及其附属公司)。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591264308","isCrawlerRequest":true}